Leonard Dipisa, MD
Nuclear Cardiology · Toms River, NJNPI 1730176611
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $350 and has fallen 75.2% since, to $87 in 2025. That places this record below the midpoint for nuclear cardiology clinicians in NJ, where the typical reported total is $3,343.
Across 85 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$238
- Boston Scientific$224
- Novartis$161
- Atricure, Inc.$114
- Astellas Pharma US Inc$113
- Merck$97
- plus $545 from 13 others
What the payments were for
- Food & beverage$1,39493%
- Education$997%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 16 | $238 |
| Boston Scientific | 12 | $224 |
| Novartis | 10 | $161 |
| Atricure, Inc. | 1 | $114 |
| Astellas Pharma US Inc | 2 | $113 |
| Merck | 7 | $97 |
| AstraZeneca | 7 | $96 |
| E.r. Squibb & Sons, L.L.C. | 7 | $96 |
| Amgen | 5 | $67 |
| Novo Nordisk | 4 | $66 |
| Philips North America LLC | 3 | $43 |
| Johnson & Johnson | 3 | $40 |
| Irhythm Technologies, Inc. | 1 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Edwards Lifesciences | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,493 in reported general payments places this provider in the 20th percentile of 34 nuclear cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 311 | $410,408 |
| EntrestoSacubitril/Valsartan | 94 | $137,457 |
| XareltoRivaroxaban | 95 | $99,682 |
| FarxigaDapagliflozin Propanediol | 14 | $21,946 |
| BrilintaTicagrelor | 16 | $18,530 |
| Rosuvastatin Calcium | 793 | $15,210 |
| CrestorRosuvastatin Calcium | 15 | $11,887 |
| Metoprolol Succinate | 581 | $11,534 |
| Losartan Potassium | 706 | $11,096 |
| Atorvastatin Calcium | 659 | $7,025 |
| Amlodipine Besylate | 538 | $4,215 |
| Icosapent Ethyl | 15 | $4,167 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 133 | $3,468 |
| Lisinopril | 328 | $3,413 |
| Ezetimibe | 114 | $3,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $238 | $410,408311 claims |
| NovartisEntresto | $161 | $137,45794 claims |
| Johnson & JohnsonXarelto | $40 | $99,68295 claims |
| AstraZenecaFarxiga, Brilinta, Crestor | $96 | $52,36445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 34 nuclear cardiology providers in New Jersey.
Other nuclear cardiology in Toms River
- Brett SealoveEatontown$410K
- Madhav UpadhyayaTinton Falls$89K
- Mark FinchCherry Hill$28K
- Hafeza ShaikhWillingboro$16K
- Nasser ChaudhryCherry Hill$11K
- Ralph RussoMoorestown$11K
- Anthony SauerweinMoorestown$10K
- Howard WeinbergSewell$9K
- Scott GablerVoorhees$7K
- Samuel VentrellaMoorestown$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.